BSE Pharma Sector Regulatory Filings — August 31, 2026

Exclusive licensing of TQB2102 (HER2 bispecific ADC) with three Breakthrough Therapy Designations from China's NMPA; targets HER2-low/positive breast cancer, colorectal, and biliary tract cancers. Strengthens oncology pipeline with best-in-class potential.

Positive Phase IIb EVIDENCES-X trial for Saroglitazar Mg in MASH achieved primary endpoint (resolution of steatohepatitis with no worsening of fibrosis); treatment difference of 26.5% vs placebo. Already approved in India for MASH/MASLD (2020). De-risks US/EU regulatory pathway.

First US generic inhalation product launch (fluticasone propionate/salmeterol for Advair Diskus) in 100/50 mcg and 250/50 mcg strengths. Expands complex generics portfolio; 30+ regulatory-approved facilities globally.

Completed sale of 100% stake in Broadway Hospitality Services (effective Aug 31, 2026), exiting non-core hospitality. No financials disclosed, but signals focus on core pharma business.

Participation in Nomura Asian Credit Corporate Day (Sep 4, 2026) with no UPSI disclosure. Low materiality but maintains investor engagement.

Ranked 3rd largest in India pharma (IQVIA MAT Jun'26) and 2nd largest in US generics (Repulses + MDI). Strong market position provides distribution leverage for TQB2102.

Saroglitazar Mg trial enrolled only 189 subjects (USA, Turkey, Argentina). Small sample size may limit generalizability but positive efficacy signal supports Phase III design.

Advair Diskus generic launch addresses a multi-billion-dollar US market (asthma/COPD). First-mover advantage in inhalation complex generics.

No upfront or milestone payments disclosed; drug is still under clinical evaluation with no guaranteed regulatory approvals in target markets. High execution risk.

Saroglitazar Mg remains investigational in US and EU; Phase IIb sample size (n=189) may not be sufficient for pivotal registration. Regulatory pathway uncertain.

No financial details (consideration, gain/loss) disclosed. Lack of transparency on deal terms raises questions about valuation and potential one-time impact.

No UPSI disclosure, but participation in credit-focused event may signal debt management or refinancing needs.

First complex inhalation product; manufacturing scale-up and market acceptance risks. Advair Diskus generic market may face pricing pressure from multiple competitors.

No period-over-period comparisons, insider activity, or capital allocation data available in any filing. Limits ability to assess management conviction, financial health trends, or shareholder returns.

TQB2102 is a bispecific ADC, a novel modality; clinical and commercial risks are higher than traditional small molecules.

Best-in-class potential in HER2+ breast cancer (multi-billion-dollar market). Three Breakthrough Therapy Designations accelerate regulatory pathway in China; potential for fast-track in other markets.

Positive Phase IIb data in MASH (26.5% treatment difference) positions it as a leading candidate in a high-unmet-need market. Already approved in India; could leverage Indian data for US/EU Phase III.

First US inhalation generic launch; complex generics typically command higher margins and face fewer competitors. Could drive significant revenue upside.

TQB2102 complements existing oncology portfolio; exclusive rights in India, South Africa, and 5 other emerging markets tap into growing cancer incidence in these regions.

MASH (NASH) is a multi-billion-dollar opportunity with no approved therapies in US/EU. Positive Phase IIb data could attract partnership or licensing interest from global pharma.

Exit from hospitality (Broadway) allows management to concentrate on core pharma business. Potential for improved margins and capital allocation to R&D.

First product commercialized; successful launch could pave way for additional inhalation products (e.g., other asthma/COPD generics), creating a new growth vertical.

Both companies are investing in differentiated R&D (ADCs, MASH). If successful, they could command higher valuation multiples vs. pure generics peers.

Cipla (ADC) and Zydus (MASH) are pursuing high-risk, high-reward novel therapies. This shift from generics to innovation is a key theme among top Indian pharma companies seeking to re-rate valuations.

Aurobindo's first inhalation generic launch underscores the trend of Indian pharma moving up the value chain into complex generics (inhalation, injectables, transdermals) which offer higher barriers to entry and better pricing power.

Mankind Pharma's sale of a hospitality subsidiary reflects a broader trend of pharma companies shedding non-core assets to streamline operations and focus on core therapeutic areas. Expect more such transactions.

Cipla's licensing deal targets India, South Africa, and other emerging markets, while Zydus's Saroglitazar is already approved in India. Indian pharma is leveraging domestic approvals to build global pipelines.

None of the filings provided period-over-period comparisons, insider activity, or capital allocation data. This limits the ability to assess management confidence and financial trends, highlighting a sector-wide disclosure gap for investors.

Watch for clinical trial updates (Phase I/II data) and regulatory filings in target markets. Potential partnership or milestone payments could be catalysts. [No date available]

Watch for Phase III trial initiation in US/EU and potential partnership discussions. Regulatory interactions with FDA/EMA will be key. [No date available]

Monitor market share capture, pricing trends, and revenue contribution from the inhalation launch. Competitor launches (e.g., Mylan, Hikma) could impact. [No date available]

Sep 4, 2026. Watch for any debt-related announcements or credit rating changes that may emerge from the event. [Sep 4, 2026]

Watch for further non-core divestitures or acquisitions in core pharma. The hospitality sale may be followed by other asset sales. [No date available]

Monitor for additional licensing deals or in-house development of ADCs and other novel modalities. [No date available]

Watch for data readouts from competitors (e.g., Madrigal, Intercept, Novo Nordisk) that could impact Saroglitazar's positioning. [No date available]

Watch for additional inhalation product filings/approvals (e.g., other Advair strengths, Symbicort generic). [No date available]